Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

• Intellia disclosed that a patient who suffered severe liver toxicity in its Phase 3 MAGNITUDE trial has died; FDA clinical holds on MAGNITUDE and MAGNITUDE‑2 remain in place.
• NTLA shares traded sharply lower intraday as Wall Street cut targets; RBC lowered its price target to $9 and flagged an unfavorable near‑term risk/benefit profile for the ATTR program.
• Q3 2025 results show $669.9M in cash and securities (runway into mid‑2027), with progress continuing in Intellia’s hereditary angioedema (HAE) program lonvoguran ziclumeran (lonvo‑z; NTLA‑2002).

What happened today

Intellia Therapeutics (NASDAQ: NTLA) is under intense pressure after the company said the patient who experienced Grade 4 liver enzyme and bilirubin elevations in its Phase 3 MAGNITUDE study later died. In a Nov. 6 business update, CEO John Leonard said the treating physician cited “complicating comorbidities,” and Intellia is working with investigators and outside experts on a risk‑mitigation plan for nexiguran ziclumeran (nex‑z; NTLA‑2001), its in vivo CRISPR therapy for transthyretin amyloidosis (ATTR). The FDA’s clinical holds on MAGNITUDE (ATTR‑CM) and MAGNITUDE‑2 (ATTR‑PN) are still in effect pending a formal hold letter. GlobeNewswire+1

Sell‑side reaction was swift. RBC Capital Markets cut its NTLA price target to $9 from $14, pointing to the patient death and the availability of alternative ATTR treatments as reasons to reassess the program’s risk/benefit trade‑off. Other firms also trimmed ratings and targets following the pause and hold.

What the latest data say about the trials

Intellia paused dosing and screening on Oct. 27 after reporting the severe liver toxicity event in MAGNITUDE; two days later the FDA imposed clinical holds on both late‑stage ATTR trials. At the time of the pause, >650 patients had been enrolled across MAGNITUDE and MAGNITUDE‑2, with >450 estimated to have been dosed. Today’s company update reiterates that the team is investigating mechanisms and developing mitigation steps.

What is nex‑z? It’s an in vivo CRISPR/Cas9 therapy intended to knock down the TTR gene in the liver after a single dose. Intellia leads development in collaboration with Regeneron. The company plans to present longer‑term Phase 1 data for ATTR‑CM at AHA 2025 on Nov. 10, which could offer additional context on durability and safety.

Earnings snapshot: liquidity and operating runway

Alongside the clinical update, Intellia posted Q3 2025 results:

• Cash, cash equivalents & marketable securities:$669.9M (vs. $861.7M at year‑end 2024), including $114.5M raised via ATM in Q3.
• Collaboration revenue:$13.8M (Q3 2024: $9.1M).
• R&D expense:$94.7M (Q3 2024: $123.4M).
• Net loss:$101.3M or ($0.92) per share (Q3 2024: ($1.34)).
  Management guides that its balance sheet funds operations into mid‑2027 and, if timelines hold, through the anticipated U.S. launch of its HAE program.

HAE program remains the counterweight

While ATTR is in the spotlight, Intellia emphasized continued progress for lonvoguran ziclumeran (lonvo‑z; NTLA‑2002) in hereditary angioedema. The Phase 3 HAELO trial finished enrollment in September, with top‑line data expected by mid‑2026 and a potential BLA submission in 2H 2026. Longer‑term Phase 1/2 data in HAE will be presented Nov. 8 at ACAAI 2025. None of these timelines were changed in the company’s Q3 update.

Street debate: platform risk or asset‑specific?

A core investor question is whether MAGNITUDE’s liver events reflect platform‑wide risk (CRISPR editing and delivery) or drug‑specific biology. Recent coverage noted company officials believe the signal may be tied to the gene target rather than Intellia’s delivery platform; still, with proven alternatives in ATTR, analysts caution that the bar for safety is high as regulators review the hold.

Near‑term catalysts and watch‑outs

• FDA clinical hold letter for MAGNITUDE and MAGNITUDE‑2: clarity on next steps and any required protocol changes.
• Scientific readouts: AHA (Nov. 10) for ATTR‑CM Phase 1 durability/safety; ACAAI (Nov. 8) for HAE longer‑term data.
• Sell‑side updates: Expect more revisions to ratings/targets as details emerge from FDA correspondence and upcoming presentations.

Bottom line

Today’s headline for NTLA is the MAGNITUDE patient death and the ongoing FDA holds. That development – and the Street’s reaction – now dominates the near‑term setup. Intellia’s cash runway and advancing HAE program provide strategic optionality, but investors will likely reserve judgment until the hold letter arrives and the company outlines a credible risk‑mitigation path for nex‑z.

This article is for information only and not investment advice.

Sources: Company press releases and filings; major financial and biotech news outlets cited throughout.